Latest California Healthline Stories
In this episode of “What the Health?” Mary Agnes Carey of Kaiser Health News, Sarah Karlin-Smith of Politico, Margot Sanger-Katz of The New York Times and Julie Appleby of Kaiser Health News discuss the problems some consumers will face with a lack of exchange-based insurance coverage in their regions. They also talk about the state of play on Capitol Hill and in the states concerning initiatives to lower prescription drug costs.
Hospital use of two popular heart medicines, nitroprusside and isoproterenol, dramatically dropped after the prices for both soared.
Three years ago, only about a quarter of the nation’s large employers were very confident they would have a health plan in 10 years. That number has now risen to 65 percent.
The FDA granted approval for Spinraza in late December for use on children and adults with spinal muscular atrophy. Insurance coverage is mostly focused on infants and children.
Kaiser Health News examines the role of PBMs in the prescription drug-pricing pipeline.
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.
A little-noticed provision in President Donald Trump’s executive order on drug prices may offer a clue to why Big Pharma hasn’t opposed a bill that could bleed their balance sheets of millions of patients.
Documents examined by Kaiser Health News shed light on the workings of the Trump administration’s “Drug Pricing and Innovation Working Group.”
With the cost of medications up 300 percent in the past decade, supporters see this as a first step to rein in prices.